
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2021

CABALETTA BIO, INC.
(Exact name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-39103
(Commission
File Number)

82-1685768
(I.R.S. Employer
Identification No.)

2929 Arch Street, Suite 600,
Philadelphia, PA
(Address of principal executive offices)

19104
(Zip Code)

(267) 759-3100
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Trading Symbol(s)</u>	<u>Name of Each Exchange on Which Registered</u>
Common Stock, par value \$0.00001 per share	CABA	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Director

On June 22, 2021, Brian Daniels, M.D. informed the Board of Directors (the “Board”) of Cabaletta Bio, Inc. (the “Company”) of his resignation as a member of the Board and all committees of the Board, effective as of June 24, 2021. There are no disagreements between Dr. Daniels and the Company on any matter relating to the Company’s operations, policies or practices.

Election of Director

On June 24, 2021, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company appointed Scott C. Brun, M.D. to join the Board, effective as of June 24, 2021. Dr. Brun will serve as a Class I director until his term expires at the 2023 annual meeting of stockholders at which time he will stand for election by the Company’s stockholders. The Board determined that Dr. Brun is independent under the listing standards of Nasdaq. Dr. Brun was also appointed to serve on the Nominating and Corporate Governance and Audit Committees of the Board.

Effective as of June 24, 2021, the Nominating and Corporate Governance Committee of the Board is composed of Mark Simon, Dr. Brun and Catherine Bollard, MBChB, M.D., the Audit Committee of the Board is composed of Richard Henriques, Dr. Brun and Mr. Simon and the Compensation Committee of the Board is composed of Dr. Bollard, Mr. Henriques, and Mr. Simon.

As a non-employee director, Dr. Brun will receive cash compensation and an equity award for his Board service in accordance with the Company’s Amended and Restated Non-Employee Director Compensation Policy. Dr. Brun is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Brun and any other persons pursuant to which he was selected as a director. In addition, Dr. Brun will enter into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors.

On June 28, 2021, the Company issued a press release announcing Dr. Brun’s appointment to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.

Item 9.01. Exhibits

(d) Exhibits

99.1 [Press Release Issued by the Company on June 28, 2021, furnished herewith.](#)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CABALETTA BIO, INC.

Date: June 28, 2021

By: /s/ Steven Nichtberger
Steven Nichtberger, M.D.
President and Chief Executive Officer



Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors

Dr. Brun's early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta's rapidly emerging pipeline

PHILADELPHIA, June 28, 2021 – Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointment of veteran biopharmaceutical leader, Scott Brun, M.D., to its Board of Directors. Dr. Brun has over 20 years of wide-ranging drug development and business development experience, including his time as Vice President and Head of Pharmaceutical Development at AbbVie Inc., or AbbVie, and the predecessor company, Abbott Laboratories, and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities.

“Scott is an accomplished physician and executive whose pharmaceutical perspective on early and late-stage clinical development, strategic partnership and investment experience, including particular expertise in clinical development of products in the autoimmune, neurologic, and renal disease therapeutic areas, aligns well with our rapidly advancing pipeline. His expertise will be particularly valuable to Cabaletta as we advance our lead program, DSG3-CAART, in mucosal pemphigus vulgaris,” said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta. “We welcome him to the Board of Directors and look forward to his contributions to our strategic and operational objectives as we seek to increase shareholder value.”

Dr. Brun spent two decades at AbbVie and Abbott Laboratories, the predecessor company, where he was most recently Vice President of Scientific Affairs and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within AbbVie's R&D therapeutic areas as well as technology platforms of interest. Previously, Dr. Brun served as Vice President and Head of Pharmaceutical Development. During his tenure, Dr. Brun oversaw a global organization with responsibilities for AbbVie's entire portfolio of early and late-stage clinical pre-registration pipeline compounds as well as marketed compounds within oncology, neurology, immunology, renal, infectious disease, and women's and men's health therapeutic areas. Earlier in his career, he held positions of increasing leadership responsibility in drug development within the R&D organization at Abbott Laboratories. Dr. Brun is currently President at Gold Mast Consulting, LLC, an advisory firm he founded to provide technical advice and strategic guidance related to biopharmaceutical research and development, pipeline portfolio management, commercialization of new therapeutics and strategic communications related to R&D activities. Dr. Brun received his B.S. in Biochemistry from the University of Illinois at Urbana-Champaign and earned his M.D. from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School.

“Based on a robust and elegant scientific platform, Cabaletta has the potential to revolutionize the treatment landscape for autoimmune disease and I look forward to contributing to the Board

of Directors and partnering with leadership team as they seek to achieve their mission of providing a deep and durable treatment for patients with B cell-mediated autoimmune diseases,” said Scott Brun, M.D.

Dr. Brun will become a member of the Audit Committee and the Nominating and Corporate Governance Committee. Dr. Brun will succeed Brian Daniels, M.D., who resigned from the Board of Directors effective June 24, 2021, and subsequently joined the Scientific Advisory Board. Dr. Daniels has served on Cabaletta’s Board of Directors since October 2018.

“Speaking for the entire leadership team and his colleagues on the Board of Directors at Cabaletta, I want to thank Dr. Daniels for his keen insights and thoughtful, probing questions over the last three years and his service to the Board of Directors. His advice and counsel proved invaluable. We are fortunate to be able to continue our engagement with Dr. Daniels moving forward as a member of our Scientific Advisory Board,” continued Dr. Nichtberger.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Forward-Looking Statements

This press release contains “forward-looking statements” of Cabaletta within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding the company’s business plans and objectives; expectations regarding the progress and results of its DesCAARTes™ Phase 1 trial; the effectiveness and timing of product candidates that Cabaletta may develop, including in collaboration with academic partners; statements regarding regulatory filings regarding its development programs; and the anticipated contribution of the members of our board of directors and our executives to our operations and progress.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: Cabaletta’s ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its clinical trials of DSG3-CAART; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to the impact of public health epidemics affecting countries or regions in which we have operations or do business, such as COVID-19; and the risk that the initial or interim results of clinical studies will not be predictive of future

results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Cabaletta's most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com